Majedie Asset Management’s GSK GSK Stock Holding History

Majedie Asset Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$8.13M	Sell	149,720 -33,689	-18%	-$1.83M	0.67%	53
2021 Q4	$10.1M	Buy	183,409 +14,583	+9%	+$759K	0.77%	40
2021 Q3	$8.06M	Sell	168,826 -967	-0.6%	-$48.6K	0.61%	59
2021 Q2	$8.46M	Sell	169,793 -28,009	-14%	-$1.35M	0.56%	63
2021 Q1	$8.83M	Buy	197,802 +31,510	+19%	+$1.43M	0.64%	49
2020 Q4	$7.66M	Sell	166,292 -17,437	-9%	-$801K	0.59%	47
2020 Q3	$8.65M	Sell	183,729 -4,324	-2%	-$217K	0.64%	38
2020 Q2	$9.59M	Sell	188,053 -76,281	-29%	-$3.91M	0.73%	31
2020 Q1	$12.5M	Sell	264,334 -31,269	-11%	-$1.67M	1.16%	18
2019 Q4	$17.4M	Buy	295,603 +753	+0.3%	+$41.9K	1.26%	19
2019 Q3	$15.7M	Sell	294,850 -211,252	-42%	-$10.9M	1.34%	17
2019 Q2	$25.4M	Sell	506,102 -359,823	-42%	-$18.1M	1.95%	9
2019 Q1	$45.3M	Sell	865,925 -42,602	-5%	-$2.13M	3.2%	7
2018 Q4	$44.4M	Buy	+908,527	New	+$44.7M	3.3%	8

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

BCIM

Black Creek Investment Management Toronto, Ontario, Canada $1.86B AUM 15.33% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Majedie Asset Management's GSK Position: Q1 2022 in Review

Majedie Asset Management reduced its GSK (GSK) stake by 18% in Q1 2022, selling an estimated $1.83M and leaving 149,720 shares worth $8.13M. The position accounts for 0.67% of the portfolio, ranked #53.

Majedie Asset Management first reported a position in GSK in Q4 2018 and has held it in 14 quarters since. The position peaked at $45.3M in Q1 2019. 929 funds tracked by Wall St. Rank hold GSK as of Q1 2022.

Majedie Asset Management held 149,720 shares of GSK worth $8.13M as of Q1 2022.
Majedie Asset Management sold 33,689 GSK shares in Q1 2022, an estimated $1.83M.
GSK made up 0.67% of Majedie Asset Management's portfolio in Q1 2022, its #53 holding.
Majedie Asset Management first reported a position in GSK in Q4 2018 and has held it in 14 quarters since.
Majedie Asset Management's GSK position peaked at $45.3M in Q1 2019.
929 funds tracked by Wall St. Rank held GSK as of Q1 2022.

Based on Majedie Asset Management's 13F filing for Q1 2022, filed 16 May 2022.